This Article Full Text Full Text (PDF) All Versions of this Article: 90/3/1583    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallagher, J. C. Articles by Krege, J. H. Search for Related Content PubMed PubMed Citation Articles by Gallagher, J. C. Articles by Krege, J. H. Related Collections Calcium and Bone Metabolism

Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures

Bone Metabolism Section, Creighton University Medical Center (J.C.G.), Omaha, Nebraska 68131; Osteoporosis and Arthritis Research Group, University of California (H.K.G.), San Francisco, California 94143; Synarc, Inc. (H.K.G.), San Francisco, California 94143; Lilly Research Laboratories, Eli Lilly & Company (G.G.C., J.H.K.), Indianapolis, Indiana 46285; and Department of Endocrinology, William W. Backus Hospital (S.J.V.), Norwich, Connecticut 06360

Address all correspondence and requests for reprints to: Dr. John H. Krege, Lilly Research Laboratories, DC 6121, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana 46285. E-mail: krege_john_henry{at}lilly.com.

The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 µg) in the Fracture Prevention Trial. The median observation time was 21 months. Among placebo patients with one, two, or three or more prevalent vertebral fractures, 7%, 16%, and 23%, respectively, developed vertebral fractures (by Cochran-Armitage trend test, P < 0.001), and 3%, 9%, and 17% developed moderate or severe vertebral fractures (P < 0.001). Among placebo patients with mild, moderate, or severe prevalent vertebral fractures, 10%, 13%, and 28%, respectively, developed vertebral fractures (P < 0.001), and 4%, 8%, and 23% developed moderate or severe vertebral fractures (P < 0.001). Among placebo patients with zero, one, or two or more prior nonvertebral fragility fractures, 4%, 8%, and 18%, respectively, developed nonvertebral fragility fractures (P < 0.001). In the teriparatide-treated group, there was no significant increase in vertebral or nonvertebral fracture risk in these subgroups. In summary, the number and severity of prevalent vertebral fractures independently predicted the risk for new vertebral fractures, and the number of prior nonvertebral fractures predicted the risk for new nonvertebral fractures in placebo patients. However, in teriparatide-treated patients, the increased fracture risk associated with prior number and severity of fracture was not observed.

This article has been cited by other articles:

				C. MacLean, S. Newberry, M. Maglione, M. McMahon, V. Ranganath, M. Suttorp, W. Mojica, M. Timmer, A. Alexander, M. McNamara, et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern Med, February 5, 2008; 148(3): 197 - 213. [Abstract] [Full Text] [PDF]

				E. M. Lewiecki and A. J. Laster Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4215 - 4222. [Abstract] [Full Text] [PDF]